LAUSR

U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. Br J Dermatol 2017; 176: 1351–3. 3 Primary Care Dermatology Society. Actinic keratosis clinical guidance; November 2011 (last updated 2 March 2017). Available at: http://www.pcds.org.uk/clinical-guidance/actinic-keratosis-syn.solar-keratosis (last accessed 11 March 2017). 4 Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146:552–67. 5 Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159:1245–66. 6 Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis 2012; 89:241–50. 7 Fischer TC, Perosino E, Poli F et al. Chemical peels in aesthetic dermatology: an update 2009. J Eur Acad Dermatol Venereol 2010; 24:281–92. 8 Lawrence N, Cox SE, Cockerell CJ et al. A comparison of the efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131:176–81. 9 Holzer G, Pinkowicz A, Radakovic S et al. Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolevulinic acid photodynamic therapy for treating multiple actinic keratosis. Br J Dermatol 2017; 176:1155–61. 10 Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: Commonly used field-directed and lesion-directed therapies. Cutis 2012; 89:294–301.